NASDAQ

Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)

607 Thanks from members

Biodexa Pharmaceuticals (BDRX) faces severe volatility and dilution concerns following a 10,000:1 reverse split and £25m share authority, balanced against clinical trial progress for eRapa in Familial Adenomatous Polyposis.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →